Please login to the form below

Not currently logged in
Email:
Password:

Anacor

This page shows the latest Anacor news and features for those working in and with pharma, biotech and healthcare.

Pfizer mulling product sale to streamline ops; sources

Pfizer mulling product sale to streamline ops; sources

The company bought Medivation and Anacor last year - for $14bn and $5.2bn respectively - after previously failing to bring mega-mergers with AstraZeneca and Allergan to fruition. ... The Medivation deal brought in prostate cancer treatment Xtandi

Latest news

  • FDA green light for Pfizer's eczema drug FDA green light for Pfizer's eczema drug

    It needs the drug to perform as expected, having paid $5.2bn for the drug's originator Anacor in May.

  • LEO Pharma picks up AZ skin disease drugs in $1bn deal LEO Pharma picks up AZ skin disease drugs in $1bn deal

    Should the two drugs meet with regulatory approval, tralokinumab will potentially face Anacor's eczema drug crisaborole, which has recently been bought by Pfizer, and is currently under review by the

  • Pfizer adds eczema drug with $5.2bn Anacor acquisition Pfizer adds eczema drug with $5.2bn Anacor acquisition

    Pfizer adds eczema drug with $5.2bn Anacor acquisition. Expands innovative products business with non-steroidal therapy Crisaborole. ... Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema

  • GSK discontinues development of Anacor antibiotic GSK discontinues development of Anacor antibiotic

    GSK discontinues development of Anacor antibiotic. Patients developed resistance to compound during trial. ... Despite the discontinuation of the GSK2251052 collaboration, GSK is still working with Anacor through the funding of its research activities in

  • GSK suspends trials of novel antibiotic

    GlaxoSmithKline (GSK) has suspended patient enrolment in trials of GSK'052, an antibiotic for complicated urinary tract and intra-abdominal infections licensed from Anacor Pharmaceuticals. ... We will work with GSK to better understand this

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    It seems Pfizer has got the message judging from the Anacor acquisition for $5.2bn in May and a hat trick of deals this month, including the acquisitions of Medivation for

  • Deal Watch May 2016 Deal Watch May 2016

    Topping this month's DW table with a headline value of $5.2bn is Pfizer's takeover of Anacor Pharmaceuticals which exemplifies this trend. ... Licensor/ Acquired Acquirer/ Partner. Deal Type. Comments. Headline $m. Anacor/ Pfizer.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    120. Anacor Pharmaceuticals/ PharmaDerm (Sandoz). Licence†. Kerydin topical for toenail onychomycosis (approved).

  • Pharma deals during October 2013 Pharma deals during October 2013

    Valeant has agreed to pay Anacor $142.5m to settle all existing and future claims related to Anacor's contractual dispute with Dow. ... However, Anacor had sought an award of at least $215m plus injunctive relief, but the arbitrator did not grant an

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    XEN-D103 ion channel modulator for atrial fibrillation (phase I). 162.4. Anacor / Valeant.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics